Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox 10 vs 20 Injections for Refractory Overactive Bladder
NCT04124939Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of botulinum toxin type A in overactive bladder (OAB) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Numeric Pain Rating Scale at 1 day. Started Nov 2019; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04124939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124939.